ZGNX News and Press, Zogenix Inc. From 07/29/20

EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, after the market close, and will...

Zogenix ( ZGNX ) caught my eye recently as a potential newly minted biotech high-flyer . As I began looking into it I saw it has an interesting story with an uncertain outcome, one that promises many interesting twists. This article sets out my analysis of it as an investment vehicle. I am ...

With the highly volatile markets fueled by rising algorithmic and day trading, it is increasingly common to see wide swings in stocks, particularly in the biotech sector. Therefore, one must be prepared to have the courage of one's convictions and accumulate fundamentally strong stocks on dips...

Zogenix Buoyant on FDA Approval for Fintepla Zogenix ( ZGNX ) reported that the FDA has approved its Fintepla drug for treating seizures associated with Dravet syndrome. The drug may now be used for treating patients 2 years of age and older. It will be distributed under the FINTEPLA R...

Needham is unfazed by the boxed warning the FDA's requiring for Zogenix's (NASDAQ: ZGNX ) Fintepla, approved yesterday evening by the FDA for the type of epilepsy called Dravet syndrome, calling the newly endorsed treatment "transformational," and reiterating its Buy rating on the company....

Zogenix ( ZGNX -3.7% ) has experienced substantial volatility today after the FDA announced approval of Fintepla (fenfluramine) for a rare type of epilepsy called Dravet syndrome after the close yesterday, normally a bullish event despite broad market behavior. More news on: Zogenix, I...

MDC Partners (NASDAQ: MDCA ) +169%  on potential business combination with Stagwell. More news on: MDC Partners Inc., Vaxart, Inc., iBio, Inc., Stocks on the move, , Read more ...

Zogenix (NASDAQ: ZGNX ) says the Food and Drug Administration approved its Fintepla drug to treat seizures associated with Dravet syndrome, a rare form of childhood epilepsy. More news on: Zogenix, Inc., GW Pharmaceuticals plc, Healthcare stocks news, Read more ...

FINTEPLA ® significantly and substantially reduced convulsive seizure frequency in patients whose seizures were not adequately controlled on other medications, as observed in two phase 3 placebo-controlled clinical trials Commercial launch planned for July 2020 Zogenix to hos...

The following healthcare companies have filed prospectuses for mixed shelf offerings: More news on: Genprex, Inc., Syros Pharmaceuticals, Inc., ChromaDex Corporation, Healthcare stocks news, , Read more ...